Search our Database of Scientific Publications and Authors

I’m looking for a
    Vasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitis.
    • Authors:
    • Loic Guillevin
      National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis
      France
    Nat Rev Rheumatol 2017 Sep 3;13(9):518-519. Epub 2017 Aug 3.
    French Vasculitis Study Group, Referral Center for Rare Systemic and Autoimmune Diseases: Vasculitis and Scleroderma, Hôpital Cochin, APHP, Université Paris Descartes, Paris, France.

    Similar Publications

    Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
    N Engl J Med 2017 05;376(20):1921-1932
    From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center, Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge, Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.), and Research and Development, Statistics, Programming, and Data Standards (S.M.), GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumünster, Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona (M.C.C.); the Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah School of Medicine, Salt Lake City (G.J.G.).
    Background: Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis. Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with polyangiitis.

    Methods: In this multicenter, double-blind, parallel-group, phase 3 trial, we randomly assigned participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had received treatment for at least 4 weeks and were taking a stable prednisolone or prednisone dose to receive 300 mg of mepolizumab or placebo, administered subcutaneously every 4 weeks, plus standard care, for 52 weeks. Read More
    Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
    Autoimmun Rev 2017 Jan 23;16(1):1-9. Epub 2016 Sep 23.
    Hospices civils de Lyon, Hôpital Louis Pradel, Service de pneumologie - centre national de référence des maladies pulmonaire rares, Université de Lyon, Université Claude Bernard Lyon I, UCBL-INRA-ENVL-EPHE, UMR754, IFR128, Lyon, France.
    Objective: To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA.

    Methods: Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patients asthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease.

    Results: The study population included 157 patients (mean age 49. Read More
    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting as diffuse myositis.
    BMC Musculoskelet Disord 2014 Nov 21;15:388. Epub 2014 Nov 21.
    Department of Internal Medicine, Université de Sherbrooke, 3001 12e Avenue, Fleurimont, QC J1H 5N4, Canada.
    Background: Eosinophilic granulomatosis with polyangiitis is a complex multisystemic syndrome with heterogeneous presentation. Most often, there is a clinical history of asthma or other atopic conditions, and current presentation generally includes signs of cutaneous or pulmonary involvement. Very few reports described myalgia or weakness as the chief complaint. Read More
    [Acute cerebral sinus-thrombosis due to polyangiitis overlap syndrome with granulomatosis with polyangiitis (Wegener's granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)].
    Zh Nevrol Psikhiatr Im S S Korsakova 2016 ;116(12. Vyp. 2):30-35
    Pavlov First St.-Petersburg State Medical University, St.-Petersburg, Russia; Pavlov First St.-Petersburg State Medical University, St.-Petersburg, Russia.
    A brief review of literature is made on the problem of modern classification, diagnosis and treatment of systemic vasculitis. The authors present a clinical case of a 40-YO male, in whom the disease started with focal neurological signs: epileptic seizures, disorder of consciousness, light euphoria, nasolabial fold insufficiency and left upper extremity hypoesthesia. Initial examination revealed upper sagittal sinus together with right lateral sinus thrombosis with forming of bilateral frontal lobe's hemorrhages; development of stable thrombocytopenia and platelet antibodies in blood species as well as hyperhomocysteinemia and a MTHFR gene mutation. Read More